19.10.2023 13:40:05
|
Bio-Techne Promotes Kim Kelderman To Succeed Chuck Kummeth As President And CEO
(RTTNews) - Bio-Techne Corp. (TECH) announced Thursday that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer, effective February 1, 2024. Kelderman will also become a member of the Board of Directors on the same day.
Prior to assuming CEO responsibilities, Kelderman will become Chief Operating Officer, effective November 1, 2023, where he will be responsible for the day-to-day operations of the Company.
Kelderman succeeds Chuck Kummeth, who will be retiring from the company after serving as President, Chief Executive Officer and Board Director for the past 10 years.
Kummeth will continue to provide transition support to Kelderman as a Senior Advisor from February 1, 2024 until his retirement on July 1, 2024.
Kelderman is a proven business leader with more than 30 years of operational and strategic experience. Since joining Bio-Techne in 2018, Kelderman has served as President of its Diagnostics and Genomics Segment (DGS).
Kelderman also currently serves on the Board of Directors of StatLab Medical Products. Prior to joining Bio-Techne, Kelderman led three different businesses of increasing scale and complexity at Thermo Fisher Scientific. Previously, Kelderman served as Senior Segment leader at Becton Dickinson where he managed its global BD Vacutainer business.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corpmehr Nachrichten
21.11.24 |
S&P 500-Papier Bio-Techne-Aktie: So viel hätte eine Investition in Bio-Techne von vor einem Jahr abgeworfen (finanzen.at) | |
14.11.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel Gewinn hätte ein Bio-Techne-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
07.11.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel hätten Anleger mit einem Investment in Bio-Techne von vor 5 Jahren verdient (finanzen.at) | |
31.10.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel Verlust wäre bei einem Investment in Bio-Techne von vor 3 Jahren angefallen (finanzen.at) | |
30.10.24 |
Schwache Performance in New York: S&P 500 präsentiert sich zum Handelsende schwächer (finanzen.at) | |
30.10.24 |
S&P 500-Handel aktuell: So entwickelt sich der S&P 500 aktuell (finanzen.at) | |
30.10.24 |
Pluszeichen in New York: Börsianer lassen S&P 500 zum Start steigen (finanzen.at) | |
29.10.24 |
Ausblick: Bio-Techne stellt Zahlen zum jüngsten Quartal vor (finanzen.net) |